Overview

Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD)

Status:
Completed

Trial end date:
2010-02-01

Target enrollment:

Participant gender:

Summary

The objective of this study is to provide initial safety and tolerability information of intravitreal POT-4 for treatment of patients with AMD

Phase:

Phase 1

Details

Lead Sponsor:

Potentia Pharmaceuticals, Inc.